Drugs / MG4101
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01212341 | Sep 2010 → Aug 2012 | cancer, lymphoma | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03778619 | Nov 2018 → Apr 2020 | non-Hodgkin lymphoma | GC Cell Corporation | Unknown | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT03578198 | Nov 2018 → Apr 2022 | indolent B-cell non-Hodgkin lymphoma | Seoul National University Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT03349502 | Nov 2017 → Mar 2020 | acute myeloid leukemia | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02854839 | Nov 2016 → Sep 2018 | hepatocellular carcinoma | GC Cell Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02008929 | Aug 2014 → Oct 2015 | hepatocellular carcinoma | Samsung Medical Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MG4101 | “Allogeneic natural killer (NK) cells (MG4101) were manufactured from normal healthy donor who underwent leukapheresis.” NCT01212341 ↗ |
| Known as | Allogeneic natural killer (NK) cells | “Allogeneic natural killer (NK) cells (MG4101) were manufactured from normal healthy donor who underwent leukapheresis.” NCT01212341 ↗ |
| Modality | Cell therapy | “Allogeneic natural killer (NK) cells (MG4101) were manufactured from normal healthy donor who underwent leukapheresis.” NCT01212341 ↗ |
| Route | Intravenous | “MG4101 will be administered intravenously” NCT03349502 ↗ |